Michael-Titus A, Bousselmame R, Costentin J
Unité de Neuropsychopharmacologie Expérimentale, U.R.A. 1170 du C.N.R.S., Faculté de Médecine and Pharmacie de Rouen, Saint-Etienne du Rouvray, France.
Eur J Pharmacol. 1990 Oct 9;187(2):201-7. doi: 10.1016/0014-2999(90)90007-s.
In the hot plate test, the dopamine D2 receptor agonist RU 24926 as well as the mixed dopamine D1/D2 receptor agonist apomorphine dose dependently increased the nociceptive threshold of mice, as expressed by the jump latency. The dopamine D1 receptor agonist SKF 38393 was ineffective on this parameter. The effect of RU 24926 was antagonized by the dopamine D2 specific receptor antagonist sulpiride but not by the dopamine D1 specific receptor antagonist SCH 23390. It was not increased by SKF 38393. However, the effect of apomorphine was partially but significantly reduced by SCH 23390. Inhibitors of enkephalin-degrading peptidases (thiorphan and bestatin injected i.c.v. or acetorphan injected i.v.) did not potentiate the effect of apomorphine whereas the delta opioid antagonist IC 154, 129 did not reverse the apomorphine-induced analgesia. Finally, the effect of apomorphine was significantly decreased in mice rendered tolerant to morphine. It is concluded that, in mice, the antinociceptive effect induced by apomorphine results mainly from stimulation of D2 receptors. This stimulation probably involves an endogenous opioid, different from enkephalins, which acts at mu opioid receptors.
在热板试验中,多巴胺D2受体激动剂RU 24926以及多巴胺D1/D2受体混合激动剂阿扑吗啡均剂量依赖性地提高了小鼠的痛觉阈值,以跳跃潜伏期表示。多巴胺D1受体激动剂SKF 38393对该参数无效。RU 24926的作用被多巴胺D2特异性受体拮抗剂舒必利拮抗,但未被多巴胺D1特异性受体拮抗剂SCH 23390拮抗。它不会因SKF 38393而增强。然而,阿扑吗啡的作用被SCH 23390部分但显著地降低。脑啡肽降解肽酶抑制剂(脑啡肽酶抑制剂和贝司他汀脑室内注射或醋托啡静脉注射)并未增强阿扑吗啡的作用,而δ阿片受体拮抗剂IC 154,129并未逆转阿扑吗啡诱导的镇痛作用。最后,在对吗啡产生耐受性的小鼠中,阿扑吗啡的作用显著降低。结论是,在小鼠中,阿扑吗啡诱导的抗伤害感受作用主要源于对D2受体的刺激。这种刺激可能涉及一种不同于脑啡肽的内源性阿片类物质,其作用于μ阿片受体。